1. Data & Insights

The New Playbook for Patient Support Programs: Flexibility, Focus, and Forward-Thinking

Written by Posted on Less than 0 min read

Today’s guest post comes from Josh Marsh, Vice President and General Manager, Sonexus™ Access and Patient Support at Cardinal Health.

Josh discusses how patient support programs are evolving, including the shift toward outsourcing individualized hub functions. He lists five characteristics pharmaceutical companies should look for when evaluating outsourced support for long-term program success.

To learn more, download Cardinal Health’s latest industry survey on hub model management: A New Era for Patient Support Programs.

Read on for Josh’s insights.

Read more »

© 2006-2025 HMP Omnimedia, LLC d/b/a Drug Channels Institute, an HMP Global Company. All rights reserved. This Feed is for personal non-commercial use only.

       
View Original Article
Post Views: 39
Member since
Expert insights from Dr. Adam J. Fein on pharmaceutical economics and the drug distribution system. https://www.drugchannels.net/
Do you like Drug Channels's articles? Follow on social!

More from Drug Channels

  1. Data & Insights

If Banks Sync Data in Real Time, Why Can’t Patient Services?

Today’s guest post comes from George Moore, Chief Information Technology Officer at CareMetx. While banks and logistics companies update data instantly, patient services often rely on delayed, batch-based systems. George examines the challenges of this model and the potential for real-time synchronization to improve coordination and accelerate access to therapy. To learn more, download the […]
2 min read
0
  1. Media & Marketing

Three Areas to Watch: The Inflation Reduction Act and Prescription Pricing

Today’s guest post comes from H. John Beardsley, Senior Vice President of Corporate Strategy at CoverMyMeds John discusses how the new maximum fair prices (MFPs) published by the Centers for Medicaid & Medicare Services (CMS) will affect medication affordability, formulary negotiations, evidence-based strategies, and other aspects of the market. To learn more, register for CoverMyMeds’ […]
2 min read
0
  1. Data & Insights

From Data Gaps to Revenue Gains: Harnessing the Power of Comprehensive Data to Drive GTN

Today’s guest post comes from Thomas Luby, Sr. Vice President, Business Development at PHIL. Thomas discusses the challenges brands face as they manage gross-to-net (GTN) performance while simultaneously enhancing patient access and adherence. He lists the key performance indicators that can help brands improve GTN. To learn more, watch PHIL’s free on-demand webinar: Four Patient Access […]
2 min read
0
  1. Trends & External Forces

The Big Three PBMs’ 2026 Formulary Exclusions: MFP, Private Label Biosimilars, and Direct-to-Patient Threats for PBMs

For 2026, the three largest pharmacy benefit managers (PBMs)—Caremark (CVS Health), Express Scripts (Cigna), and Optum Rx (United Health Group)—have once again excluded hundreds of drugs from their standard formularies. Our updated counts appear below. The 2026 lists highlight how formulary preferences for Humira and Stelara are dominated by private-label biosimilars affiliated with the same […]
2 min read
0
  1. Agencies & Vendors

Inside Rare Disease Pharmacy: Lessons in Personalizing Care

Today’s guest post comes from Bansi Nagji, Chief Executive Officer at PANTHERx Rare. Bansi explores how the emerging model of “Rare Pharmacy” addresses the challenges rare diseases pose to patients, caregivers, and the healthcare system. His perspective highlights the role of hyper-personalization, empathy, and data in improving outcomes for individuals with rare and orphan conditions, […]
2 min read
0
  1. Data & Insights

New Drug Launches in a Self-Pay World: Why Access Strategy Matters as Much as Innovation

Today’s guest post comes from Laura Jensen, Chief Commercial Officer and President, Pharma Solutions at GoodRx. Laura argues that patient self-pay has evolved from a temporary bridge to a core access strategy for new drug launches. She examines how manufacturer-funded self-pay offers can be operational from day one. Click here to learn more about GoodRx’s […]
2 min read
0
  1. Department: HBC

Today’s Rare Disease Launches Require the Right Specialty Pharmacy Partner

Today’s guest post comes from Richard Faris, Chief Strategy & Growth Officer at PANTHERx Rare Pharmacy. Richard outlines the key factors for commercialization success when a manufacturer launches treatments for rare and orphan diseases. He explains the key considerations for choosing a specialty pharmacy network design, selecting the right pharmacy partners, and establishing patient services […]
2 min read
0
  1. Trends & External Forces

2025 Brand Drug Challenges: A GoodRx Perspective

Today’s guest post is from Dorothy Gemmell, Chief Commercial Officer and President, Manufacturer Solutions, at GoodRx. Dorothy highlights five trends to watch in 2025. She then describes how GoodRx’s Cash Point-of-Sale Solution can help brands improve gross-to-net (GTN) while also making medications more affordable for patients. Click here to download the latest GoodRx data on […]
2 min read
0
  1. Data & Insights

Unlocking the Gate: The Critical First 24 Hours of Patient Hub Engagement

Today’s guest post comes from Kristine McGaughey, Vice President, Implementation at ConnectiveRx and Sam Blake, SVP, Hub Product at ConnectiveRx. Sam and Kristine discuss the importance of the first 24 hours of a patient’s engagement with a hub services program. They outline five reasons why two components—patient enrollment and successful benefits verification—dictate the effectiveness of […]
2 min read
0
  1. Data & Insights

PBM Industry Update: Trends, Challenges, and What’s Ahead (NEW Live Video Webinar)

Dr. Adam J. Fein, president of Drug Channels Institute (DCI) and the author of Drug Channels, invites you to join him for DCI’s new live video webinar: PBM Industry Update: Trends, Challenges, and What’s Ahead This event will be broadcast live on Friday, April 4, 2025, from 12:00 p.m. to 1:30 p.m. ET This page […]
5 min read
0
  1. Data & Insights

Closing the Specialty Access Gap: How GoodRx Turns Intent Into Therapy Starts

Today’s guest post comes from Laura Jensen, Chief Commercial Officer and President, Pharma Solutions at GoodRx Laura explores the structural hurdles that slow time-to-therapy and outlines practical ways stakeholders can streamline the path from prescription intent to treatment initiation. To learn more, book a meeting with GoodRx. Read on for Laura’s insights. Read more » […]
2 min read
0
  1. Trends & External Forces

Informa Connect’s Patient Assistance & Access Programs (PAP)

Informa Connect’s Patient Assistance & Access Programs (PAP) March 18-20, 2025 | Sheraton Philadelphia Downtown PA Pre-Conference Workshops on March 17, 2025 Drug Channels readers save 10% on their registration with code 25DC10 When it comes to patient affordability, it’s difficult to imagine a more complex time for our industry. Navigating policy updates, disarming AFPs, […]
3 min read
0
  1. Trends & External Forces

Informa Connect’s Copay, Reimbursement and Access Congress 2025

Informa Connect’s Copay, Reimbursement and Access Congress 2025 November 18-20, 2025 | Hilton New Brunswick, East Brunswick, NJ Exclusive Offer–Use promo USAVE25 to save 10%* on your registration The healthcare landscape continues to evolve at an unprecedented pace, bringing new challenges and opportunities for patient access and affordability. As legislation shifts, market forces disrupt and […]
3 min read
0
  1. Trends & External Forces

Why 340B Reform Could Happen in 2025 (video)

During my recent Drug Channels Outlook 2025 video webinar, I tackled a wide range of crucial topics—including the controversial 340B Drug Pricing Program. As I explain in this video excerpt, we may finally see reform of this rapidly expanding program. What’s more, implementing the Inflation Reduction Act will disrupt the current operations of the 340B […]
2 min read
0
  1. Media & Marketing

How Large PBMs Make Money Today: A 2025 Drug Channels Update

During my PBM Industry Update: Trends, Challenges, and What’s Ahead video webinar, I explored the latest trends, emerging data, and strategic shifts transforming the pharmacy benefit management (PBM) industry. In the video clip below, I explain how PBM compensation models continue to evolve: Traditional profit sources, such as mail dispensing of nonspecialty drugs and retained […]
2 min read
0
  1. Data & Insights

What’s Next for Retail Pharmacy: Data, Debate, and Disruption (NEW Live Video Webinar)

Dr. Adam J. Fein, president of Drug Channels Institute (DCI) and the author of Drug Channels, invites you to join him for DCI’s new live video webinar: What’s Next for Retail Pharmacy: Data, Debate, and Disruption This event will be broadcast live on: Friday, June 20, 2025 12:00 p.m. to 1:30 p.m. ET Dr. Fein […]
5 min read
0
  1. Media & Marketing

Drug Channels News Roundup, February 2025: Part D vs. Pharmacies, Accumulator Madness, Wholesaler Vertical Integration, IRA vs. MDs, and a 340B Cartoon

Winter—or at least February—is almost over. Celebrate the imminent return of spring with our selection of noteworthy news from around the drug channel. In this issue: How Part D plan sponsors responded to pharmacy DIR changes Troubling new data on copay accumulators in marketplace plans DCI’s latest vertical integration visualization How the IRA will hurt […]
2 min read
0
  1. Data & Insights

The AI Advantage: Evolving Patient Engagement Strategies to Improve Outcomes

Today’s guest post comes from Stacey Little, Chief Growth Officer at AssistRx. In this guest post, Stacey explores how artificial intelligence (AI) is helping life sciences organizations move beyond fragmented support models to deliver more integrated and personalized patient engagement. She outlines three distinct approaches to structuring patient support programs and discusses how AI-driven tools—such […]
2 min read
0
  1. Department: HBC

Cigna’s Rebate-Free Pharmacy Model: Three Realities Behind Its Latest Push to Pop the Gross-to-Net Bubble

On Monday, Cigna announced that it would be abandoning traditional manufacturer rebates and moving to a new, “rebate-free” approach—essentially a point-of-sale (POS) rebate model paired with a cost-plus pharmacy reimbursement framework. Here’s the press release. Moving manufacturers’ rebates and discounts to the point of dispensing is a big win for patients, who can share in […]
2 min read
0
  1. Trends & External Forces

Drug Channels News Roundup, January 2025: Mark Cuban Fixes Healthcare, Payers’ G2N Bubble, Pharmacists Rejoice, 340B Shenanigans, and 46Brooklyn vs. Mushrooms

Get ready to climb a Crisco-covered light pole! DCI’s hometown Philadelphia Eagles are going to Super Bowl LIX! Go E-L-G-S-E-S! (No, that’s not a typo.) Before you overturn any cars, please enjoy this month’s playbook of articles, intercepted for you from the Drug Channels gridiron: Touchdown! How Mark Cuban would quarterback the U.S. healthcare system  […]
2 min read
0
Next